Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Protein tyrosine phosphatase–σ regulates hematopoietic stem cell–repopulating capacity
Mamle Quarmyne, … , Nelson J. Chao, John P. Chute
Mamle Quarmyne, … , Nelson J. Chao, John P. Chute
Published November 21, 2014
Citation Information: J Clin Invest. 2015;125(1):177-182. https://doi.org/10.1172/JCI77866.
View: Text | PDF
Brief Report Hematology Article has an altmetric score of 45

Protein tyrosine phosphatase–σ regulates hematopoietic stem cell–repopulating capacity

  • Text
  • PDF
Abstract

Hematopoietic stem cell (HSC) function is regulated by activation of receptor tyrosine kinases (RTKs). Receptor protein tyrosine phosphatases (PTPs) counterbalance RTK signaling; however, the functions of receptor PTPs in HSCs remain incompletely understood. We found that a receptor PTP, PTPσ, was substantially overexpressed in mouse and human HSCs compared with more mature hematopoietic cells. Competitive transplantation of bone marrow cells from PTPσ-deficient mice revealed that the loss of PTPσ substantially increased long-term HSC-repopulating capacity compared with BM cells from control mice. While HSCs from PTPσ-deficient mice had no apparent alterations in cell-cycle status, apoptosis, or homing capacity, these HSCs exhibited increased levels of activated RAC1, a RhoGTPase that regulates HSC engraftment capacity. shRNA-mediated silencing of PTPσ also increased activated RAC1 levels in wild-type HSCs. Functionally, PTPσ-deficient BM cells displayed increased cobblestone area–forming cell (CAFC) capacity and augmented transendothelial migration capacity, which was abrogated by RAC inhibition. Specific selection of human cord blood CD34+CD38–CD45RA–lin– PTPσ– cells substantially increased the repopulating capacity of human HSCs compared with CD34+CD38–CD45RA–lin– cells and CD34+CD38–CD45RA–lin–PTPσ+ cells. Our results demonstrate that PTPσ regulates HSC functional capacity via RAC1 inhibition and suggest that selecting for PTPσ-negative human HSCs may be an effective strategy for enriching human HSCs for transplantation.

Authors

Mamle Quarmyne, Phuong L. Doan, Heather A. Himburg, Xiao Yan, Mai Nakamura, Liman Zhao, Nelson J. Chao, John P. Chute

×

Figure 3

Selection of PTPσ– CB cells enriches for human HSCs.

Options: View larger image (or click on image) Download as PowerPoint
Selection of PTPσ– CB cells enriches for human HSCs.
(A) Mean expression...
(A) Mean expression of PTPRS in subsets of CB cells by qRT-PCR. *P < 0.0001; **P < 0.0001 (n = 3, t test). MNCs, mononuclear cells. (B) Flow cytometric analysis of PTPσ expression on CB cells and on CB CD34+CD38–CD45RA–lin– cells is shown. Numbers represent percentage of PTPσ levels. (C) Mean levels of human CD45+ hematopoietic cell and multilineage engraftment in the PB of NSG mice at 16 weeks following intrafemoral injection of human CB CD34+CD38–CD45RA–lin– cells (34+38–RA–), CD34+CD38–CD45RA–lin–PTPσ+ cells (34+38–RA–PTPσ+), or CD34+CD38–CD45RA–lin–PTPσ– cells (34+38–RA–PTPσ–). Percentage of human CD45+: *P = 0.0002, **P < 0.0001; percentage of CD13+: †P < 0.0001, ‡P < 0.0001; percentage of CD19+: §P = 0.0002, ¶P < 0.0001; percentage of CD3+: #P < 0.0001, ††P < 0.0001 (n = 11–18/group, Mann-Whitney U test). (D) Flow cytometric analysis of human CD45+ cell and multilineage engraftment is shown at 16 weeks in the PB of mice transplanted with CB 34+38–RA– cells or 34+38–RA–PTPσ– cells. Numbers represent the percentages of donor lineage cells. (E) Mean levels of human CD45+ cell engraftment are shown over time after transplant in the PB of NSG mice with parent 34+38–RA– cells, 34+38–RA–PTPσ+ cells, or 34+38–RA–PTPσ– cells. Eight weeks: *P = 0.002 (PTPσ– vs. parent), †P < 0.0001 (PTPσ– vs. PTPσ+); 12 weeks: ‡P = 0.002, §P < 0.0001; 16 weeks: ¶P = 0.0002, #P < 0.0001 (n = 11–18/group).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 4 news outlets
Blogged by 2
Posted by 5 X users
Referenced in 4 patents
On 5 Facebook pages
38 readers on Mendeley
See more details